TJ011133
Showing 1 - 6 of 6
Solid Tumor, Lymphoma Trial in China, United States (TJ011133, Pembrolizumab, Rituximab)
Active, not recruiting
- Solid Tumor
- Lymphoma
- TJ011133
- +2 more
-
Birmingham, Alabama
- +20 more
Aug 22, 2022
Advanced Solid Tumor Trial in China (TJ1133 Injection)
Recruiting
- Advanced Solid Tumor
- TJ1133 Injection
-
Bengbu, Anhui, China
- +23 more
Jul 17, 2022
Acute Myeloid Leukemia (AML), MDS(MDS) Trial in China (TJ011133)
Recruiting
- Acute Myeloid Leukemia (AML)
- Myelodysplastic Syndromes(MDS)
- TJ011133
-
Beijing, Beijing, China
- +25 more
Jul 29, 2021
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) Trial in Worldwide (Lemzoparlimab, Azacitidine, Venetoclax)
Recruiting
- Acute Myeloid Leukemia (AML)
- Myelodysplastic Syndrome (MDS)
- Lemzoparlimab
- +2 more
-
Birmingham, Alabama
- +35 more
Aug 19, 2022
Multiple Myeloma Trial in Worldwide (Lemzoparlimab, Dexamethasone, Carfilzomib)
Terminated
- Multiple Myeloma
- Lemzoparlimab
- +4 more
-
Tucson, Arizona
- +58 more
Jul 6, 2022
MDS(MDS) Trial in China (Lemzoparlimab+Azacitidine (AZA), Azacitidine (AZA))
Not yet recruiting
- Myelodysplastic Syndromes(MDS)
- Lemzoparlimab+Azacitidine (AZA)
- Azacitidine (AZA)
-
Bengbu, An Hui, China
- +44 more
Jan 29, 2023